Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: 2 - The Real Truth

Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark

Sanofi SA (NASDAQ:SNY) reported third-quarter sales of $14.55 billion (12.43 billion euros), beating the consensus of $14.46 billion. Sales increased 2.3% year over year, up 7% in constant currency.

Benzinga · Oct 24, 2025

Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy

Sanofi SA (NASDAQ:SNY) on Wednesday revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537, formerly known as INBRX-101), for alpha-1 antitrypsin deficiency (AATD) emphysema.

Benzinga · Oct 22, 2025

Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease

On Friday, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for Sanofi SA’s (NASDAQ:SNY) Rezurock (belumosudil).

Benzinga · Oct 17, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Sanofi AlphaMedix Study Hits Key Milestones In Phase 2 Study

Sanofi SA (NASDAQ:SNY) on Wednesday released topline data from a phase 2 study evaluating the efficacy and safety of AlphaMedix (212Pb-DOTAMTATE).

Benzinga · Oct 8, 2025

Sanofi Expands Insulin Savings Program To Cover All US Patients

The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ: SNY) Genzyme Corporation.

Benzinga · Sep 26, 2025

FDA Delays Key Sanofi Multiple Sclerosis Drug Decision

On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients.

Benzinga · Sep 22, 2025

Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability

Sanofi SA (NASDAQ:SNY) shared new data from the HS-OBTAIN phase 2a study, which shows that treatment with brivekimig led to clinically meaningful improvements in the primary endpoint of Hidradenitis Suppurativa Clinical Response (HiSCR50) in patients naïve to biologics with moderate-to-severe hidradenitis suppurativa (HS).

Benzinga · Sep 17, 2025

Read news from The Economist, FT, and more,
with one subscription

Britain is ‘a terrible place’ to sell medicines, says drug firm executive

Sanofi’s market access chief urges ministers to come up with a roadmap to raise spending on new treatments

The Guardian - UK · Sep 12, 2025

Roblox To Rally Around 34%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga · Sep 8, 2025

This Veeva Systems Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga · Sep 8, 2025

Why Is Sanofi Stock Falling Thursday?

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga · Sep 4, 2025

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga · Sep 4, 2025

AI might beat IQ, not EQ — but never say never

We underestimate the scale of the AI learning curve, says Paul Hudson, CEO of Sanofi.

Fortune · Sep 2, 2025

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts

A federal appeals court has revived a proposed class action accusing four major drugmakers of conspiring to restrict a government-mandated drug discount program, allegedly driving up costs for safety-net hospitals and clinics serving low-income patients.

Benzinga · Aug 11, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Jul 31, 2025

Options Corner: Sanofi's Post-Earnings Drama Delivers A Contrarian Discount

With investors concerned about overall economic stability amid the Trump administration's tariff impact, they're not in a particularly generous mood. That may be the lesson learned the hard way by global pharmaceutical giant Sanofi SA (NASDAQ:SNY). Despite delivering an earnings report that offered an encouraging view, it wasn't a perfect…

Benzinga · Jul 31, 2025

Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales

Sanofi SA (NASDAQ:SNY) reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.

Benzinga · Jul 23, 2025

Why Thermo Fischer Stock Is Rising Wednesday

Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported second-quarter 2025 adjusted earnings of $5.36 per share, beating the street view of $5.23.

Benzinga · Jul 22, 2025

Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, U.K.

Get all your
news in one place.

100's of premium titles.
One news app.

Euronews · Jul 22, 2025

Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus vaccines and add a non-mRNA vaccine to its pipeline.

The Conversation · Jul 8, 2025

New therapy teplizumab could delay type 1 diabetes by years – if caught early

For more than a century, type 1 diabetes has meant one thing: a lifetime administering insulin. But for the first time, science is breaking that paradigm – not by managing the disease, but by intercepting it before symptoms even appear.

Radio France Internationale · May 15, 2025

French drug giant Sanofi plans massive US investment to counter Trump tariffs

French pharmaceutical giant Sanofi plans to invest billions of euros to expand its manufacturing in the United States, in response to President Donald Trump’s trade policies – which include threats to impose tariffs on medicines in order to increase homegrown production.

Fortune · Apr 28, 2025

Chrissy Teigen is sharing what it was like to see her son Miles, 6 diagnosed with Type 1 diabetes: 'It was just so shocking'

“All of a sudden we were just thrown into having to learn everything imaginable the same day that he needed to start shots,” Teigen recounts.

LiveScience · Apr 25, 2025

Acne vaccine: Experimental shot for common skin condition reaches clinical trials. Here's what you need to know.

An experimental vaccine for acne could someday transform the way patients with the condition are treated, according to the company that developed the shot. However, it is still early days.

Fortune · Apr 9, 2025

Europe’s pharma titans confront von der Leyen as Trump plans ’major’ tariffs

Novo Nordisk and Sanofi were among the companies threatening to hasten their exits to the U.S., as Trump promised pharma tariffs were coming “shortly.”

inkl · Mar 27, 2025

How Diabetes Patients Are Fighting for Affordable Insulin

The World Health Organization states that there were around 830 million people living with diabetes in 2022. More than half of them weren't taking diabetes medications, including insulin, likely due to access and cost issues.

1 2 3 4 5

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.